01—Abstract
Summary
Summary of the 8-K filed July 25, 2025. Cited figures are marked; the original filing is the authoritative source.
Centene Corporation (NYSE: CNC) reported a sharply disappointing second quarter 2025, with a GAAP diluted loss per share of $(0.51) and an adjusted diluted loss per share of $(0.16), compared with GAAP diluted EPS of $2.16a and adjusted EPS of $2.42 in the year-ago quarter.
Total revenues rose to $48.7 billionb from $39.8 billion, and premium and service revenues grew 18% to $42.5 billion, driven by PDP membership growth, Marketplace market growth and Medicaid rate increases. However, the health benefits ratio jumped to 93.0% from 87.6%, reflecting a reduction in the estimated 2025 Marketplace risk adjustment revenue transfer, higher Marketplace medical costs, elevated Medicaid behavioral health, home health and high-cost drug spending, and an increase to the Medicare Advantage premium deficiency reserve. Management described the results as disappointing and said it is working to restore the earnings trajectory.
On a more constructive note, SG&A leverage improved, with the SG&A expense ratio falling to 7.1% from 8.0%, and operating cash flow of $1.8 billionc was supported by improved pharmacy rebate remittance timing. Balance sheet metrics were stable: total debt was $17.6 billion, debt-to-capitalization was 39.0%, and the company had no borrowings on its $4.0 billion revolver. Membership reached 28.0 million, with Marketplace up roughly 33% year over year to 5.9 million, while TRICARE eligibles (2.8 million in the prior year) no longer appear in the total.
Notably, Centene did not provide 2025 earnings guidance in this release, deferring it to the conference call. Investors should focus on that guidance, the durability of Marketplace and Medicaid medical cost trends, and the timing of the Marketplace risk adjustment true-up, as these will determine whether the second-half earnings recovery management is targeting is achievable.
02—Key points
Key Highlights
- GAAP diluted loss per share of $(0.51) versus $2.16 in Q2 2024; adjusted diluted loss per share of $(0.16) versus $2.42, a swing driven primarily by a reduction in the net 2025 Marketplace risk adjustment revenue transfer estimate.
- Health benefits ratio rose to 93.0% from 87.6%, pressured by Marketplace medical costs, Medicaid behavioral health, home health and high-cost drugs, and a Medicare Advantage premium deficiency reserve increase.
- Total revenues grew 22% to $48.7 billion and premium and service revenues rose 18% to $42.5 billion, led by Medicare (+58%, driven by PDP) and Commercial (+18%, driven by Marketplace).
- SG&A expense ratio improved to 7.1% from 8.0%, reflecting expense leverage over higher revenues and PDP growth.
- Total at-risk membership rose to 28.0 million from 25.7 million, with Marketplace up to 5.9 million from 4.4 million, while Traditional Medicaid declined to 11.2 million from 11.6 million due to redeterminations.
- Operating cash flow of $1.8 billion was boosted by improved pharmacy rebate remittance timing; days in claims payable fell to 47 from 54 a year earlier.
- No 2025 earnings guidance was included in the release; management will provide expectations on the July 25, 2025 conference call.
03—Questions
Frequently Asked Questions
Why did Centene swing to a GAAP loss in Q2 2025?
The primary driver was a reduction in the company's estimate of its net 2025 Marketplace risk adjustment revenue transfer, combined with higher Marketplace medical costs and elevated Medicaid and Medicare Advantage medical expenses. These pushed the health benefits ratio to 93.0%, leaving GAAP net loss attributable to Centene of $(253) million for the quarter.
Did Centene update its full-year 2025 outlook?
Not in this press release. The company stated it would provide 2025 earnings expectations on its July 25, 2025 conference call, so investors should review the call commentary for updated guidance.
Is Centene's balance sheet and liquidity under pressure?
Liquidity appears adequate. The company held $37.5 billion in cash, investments and restricted deposits, $14.5 billion in cash and equivalents, and had no borrowings under its $4.0 billion revolver. Debt-to-capitalization improved to 39.0% from 41.2% at year-end 2024, though long-term debt declined only modestly and cash flow timing contributed to operating cash flow.
Why did revenue grow strongly while earnings fell?
Revenue growth came largely from Medicare PDP membership and premium rate increases, plus Marketplace market growth. However, medical costs grew faster than premiums, and the prior-year quarter had benefited from favorable Marketplace risk adjustment, so the mix shift toward lower-margin and higher-cost business compressed margins.
Is the Q2 loss a one-time event or a sign of a longer-term problem?
Management acknowledged the results were disappointing and said it understands the trends behind them, but the release attributes much of the decline to specific items such as the Marketplace risk adjustment estimate change. Whether the issue is cyclical or structural depends on whether elevated Medicaid behavioral health, home health and high-cost drug trends persist, which will be evident in future quarterly HBR results.
04—Continue